Dementia syndromes: Evaluation and treatment

Expert Review of Neurotherapeutics

Volumn 7, Issue 4, 2007, Pages 407-422

  Scott, Kevin R ^c   Barrett, Anna M ^a,b  

^a KESSLER FOUNDATION   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; Cognition; Dementia donepezil; Galantamine; Memory; Rivastigmine; Vascular dementia

Indexed keywords

ALPHA TOCOPHEROL; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CHOLINESTERASE INHIBITOR; CURCUMIN; CYANOCOBALAMIN; DIPHENHYDRAMINE; DONEPEZIL; FLUOXETINE; FOLIC ACID; GALANTAMINE; GINKGO BILOBA EXTRACT; HALOPERIDOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEMANTINE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PRAVASTATIN; QUETIAPINE; RIVASTIGMINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TACRINE; TESTOSTERONE; UNINDEXED DRUG; VALPROIC ACID;

AGITATION; ALPHA TOCOPHEROL DEFICIENCY; ALZHEIMER DISEASE; ANDROGEN DEFICIENCY; ANEMIA; AROMATHERAPY; ARTHRITIS; BRAIN DAMAGE; CANCER CLASSIFICATION; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; CYANOCOBALAMIN DEFICIENCY; DELUSION; DEMENTIA; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXERCISE; FOLIC ACID DEFICIENCY; FRONTOTEMPORAL DEMENTIA; HALLUCINATION; HEALTH CARE QUALITY; HORMONE SUBSTITUTION; HUMAN; LIVER TOXICITY; LOW DRUG DOSE; MEMORY DISORDER; META ANALYSIS; MIXED DEPRESSION AND DEMENTIA; MONOTHERAPY; MULTIINFARCT DEMENTIA; MULTIPLE CYCLE TREATMENT; MUSIC THERAPY; NEUROIMAGING; NEUROSYPHILIS; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PSEUDODEMENTIA; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REVIEW; SEDATION; SIDE EFFECT; SYSTEMATIC REVIEW; THIAMINE DEFICIENCY; THYROID DISEASE; UNSPECIFIED SIDE EFFECT;

DEMENTIA; HUMANS; NEUROPSYCHOLOGICAL TESTS;

EID: 34247204182     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.7.4.407     Document Type: Review

References (38)

1. American Psychiatric Association. Dementia of the Alzheimer's type. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. American Psychiatric Association, Washington DC, USA (1994).
2. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E. Clinical disgnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group. Neurology 34, 939-944 (1985).
3. Hebert L, Scherr P, Bienias J, Bennett D, Evans D. Alzheimer disease in the US population: prevalence estimates using the census. Arch. Neurol. 60(8), 1119-1122 (2003).
4. Bilker J. Practical Neurology (2nd Edition). Lippincott Williams & Wilkins, PA, USA (2002).
5. Folstein M, Folstein S, McHugh P. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12(3), 189-198 (1975).
6. Blessed G, Tomlinson B, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br. J. Psychiatry 114, 797-811 (1968).
7. Rosen W, Mohs R, Davis K. A new rating scale for Alzheimer's disease. Am. J. Psychiatry 141(11), 1356-1364 (1984).
8. McGurn B, Starr J, Topfer J et al. Pronunciation of irregular words is preserved in dementia, validating premorbid IQ estimation. Neurology 62(7), 1184-1186 (2004).
9. Barrett A, Eslinger P, Ballentine N, Heilman K. Unawareness of cognitive deficit (cognitive anosognosia) in probable AD and control subjects. Neurology 64(4), 693-699 (2005).
10. Crum R, Anthony J, Bassett S, Folstein M. Population-based norms for the mini-mental state examination by age and educational level. JAMA 269(18), 2386-2391 (1993).
11. Grigoletto F, Zappala G, Anderson D, Lebowitz B. Norms for the mini-mental state examination in a healthy population. Neurology 53(2), 315-320 (1999).
12. Borson S, Scanlan J, Chen P, Ganguli M. The Mini-cog as a screen for dementia validation in a population-based sample J. Am. Geriatr. Soc. 51(10), 1451-1454 (2003).
13. Weytingh M, Bossuyt P, Crevel H. Reversible dementia more than 10% or less than 1%? A quantitative review. J. Neurol. 242(7), 466-471 (1995).
14. Knopman D, DeKosky S, Cummings J. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56(9), 1143-1153 (2001).
15. Sunderland T, Linker G, Mirza N, Putnam K. Decreased β-amyloid 42 and increase tau levels in cerebrospinal fluid of patients with Alzheimer's disease. JAMA 289(16), 2094-2103 (2003).
16. Clark C, Xie S, Chittams J et al. Cerebrospinal fluid tau and β-amyloid how well do these biomarkers reflect autospy-confirmed dementia diagnoses? Arch. Neurol. 60(12), 1696-1702 (2003).
17. Andreasen N, Minthon L, Davidsson P et al. Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer's disease in clinical practice. Arch. Neurol. 58(3), 373-379 (2001).
18. Silverman D, Small G, Chang C et al. Positron emission tomography in evaluation of dementia regional brain metabolism and long-term outcome. JAMA 286, 2120-2127 (2001).
19. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease: FDG-PET studies in MCI and AD. Eur. J. Nucl. Med. Mol. Imaging 32, 486-510 (2005).
20. Lim A, Tsuang D, Kukull W et al. Clinico-neuropathological correlation of Alzheimer's disease in a community-based series. J. Am. Geriatr. Soc. 47, 564-569 (1999).
21. Zamrini E, DeSanti S, Tolar M. Imaging is superior to cognitive testing for early diagnosis of Alzheimer's disease. Neurobiol. Aging 25, 685-691 (2004).
22. Petersen R, Stevens J, Ganguli M, Tangalos E, Cummings J, DeKosky S. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56, 1133-1142 (2001).
23. Bozoki A, Giodani B, Heidebrink J, Berent S, Foster N. Mild cognitive impairments predict dementia in nondemented elderly patients with memory loss. Arch. Neurol. 58, 411-416 (2001).
24. Morris J, Storandt M, Miller J et al. Mild cognitive impairment represents early-stage Alzheimer's disease. Ach. Neurol. 58(3), 397-405 (2001).
25. Bennett D, Wilson R, Schneider J et al. Natural history of mild cognitive impairment in older patients. Neurology 59(2), 198-205 (2002).
26. Birks B, Flicker L. Donepezil for mild cognitive impairment. Cochrane Database Syst. Rev. 3, CD006104 (2006).
27. Petersen R, Thomas R, Grundman M et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J. Med. 352(23), 2379-2388 (2005).
28. Salloway S, Ferris S, Kluger A et al. Efficacy of donepezil in mild cognitive impariment: a randomized placebo-controlled trial. Neurology 63(4), 651-657 (2004).
29. Mayor S. Regulatory authorities review use of galantamine in mild cognitive impairment. Br. Med. J. 330, 276 (2005).
30. Perl D. Neuropathology of Alzheimer's disease and related disorders. Neurol. Clin. 18(4), 847-864 (2000).
31. Tiraboshi P, Hansen L, Thal L, Corey-Bloom J. The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology 62, 1984-1989 (2004).
32. Gearing M, Mirra S, Hedreen J, Sumi S, Hansen L, Heyman A. Neuropathology confirmation of the clinical diagnosis of Alzheimer's disease. Neurology 45(3), 461-466 (1995).
33. Kukull W, Larson E, Reifler B, Lampe T, Yerby M, Hughes J. The validity of 3 clinical diagnostic criteria for Alzheimer's disease. Neurology 40(9), 1364-1369 (1990).
34. Neary D, Snowden JS, Gustafson L et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 51(6), 1546-1554 (1998).
35. McKeith L, Galasko D, Kosaka K et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47(5), 1113-1124 (1996).
36. Aarsland D, Andersen K, Larsen J, Lolk A, Nielsen H, Kragh-Sorensen P. Risk of dementia in Parkinson's disease. A community based prospective study. Neurology 56(6), 730-736 (2001).
37. Emre M. Dementia in Parkinson's disease: cause and treatment. Curr. Opin. Neurol. 17(4), 399-404 (2004).
38. Jankovic J, Tolosa E, Jankovic JJ TE (Eds). Parkinson's Disease and Movement Disorders (4th Edition). Lippincott Williams & Wilkins Philadelphia, USA (2002).